Currently, EGFR tyrosine kinase inhibitors (EGFR‐TKIs) are widely used as the first‐line standard of care for patients with EGFR mutation‐sensitive advanced NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.